Fenofibrate Therapy in Special Populations

Renal Impairment Considerations

The American College of Cardiology recommends that fenofibrate should be avoided in patients with severe renal impairment (eGFR <30 mL/min/1.73 m²) 1
For patients with mild to moderate renal impairment, the initial dose of fenofibrate should not exceed 54 mg/day, and dose increases should be made with caution after evaluating effects on renal function and lipid levels, as suggested by the American College of Cardiology and the American Journal of Kidney Diseases 1, 2
Renal function should be monitored before starting fenofibrate, within 3 months after initiation, and every 6 months thereafter, according to the American College of Cardiology 1

The American College of Cardiology suggests that fenofibrate may be considered with a low- or moderate-intensity statin only if benefits outweigh potential risks 1
The American College of Cardiology also recommends that gemfibrozil should not be used with statins due to increased risk of muscle symptoms and rhabdomyolysis 1
Monitoring for potential adverse effects, including renal function, is crucial when using fenofibrate, especially in combination with statins, as recommended by the American College of Cardiology and the American Journal of Kidney Diseases 1, 2